TABLE 3

Assessment of the effect of silexan on phenotyping metrics given as ratios for silexan over placebo periods

CYP	Parameter^a	Sample Size	Ratio	90% CI	CV_intra%
1A2	AUC_0–t of caffeine in plasma	16	0.869	0.786–0.961	16.2
1A2	Molar paraxanthine / caffeine plasma concentration ratio 6 h post-dose	16	1.16	0.956–1.414	32.2
2C9	AUC_0–t of tolbutamide in plasma	16	1.035	0.973–1.101	10.0
2C9	Tolbutamide plasma concentration 24 h post-dose	16	1.106	0.970–1.261	21.3
2C19	AUC_0–t of omeprazole in plasma	16	1.143	0.810–1.614	59.9
	Molar omeprazole / 5-OH-omepazole plasma concentration ratio 3 h post-dose	15^b	1.044	0.842–1.294	34.3
	Molar omeprazole / 5-OH-omepazole AUC_0–t ratio	16	1.111	0.998–1.237	17.4
2D6	AUC_0–t of dextromethorphan in plasma	15^c	1.046	0.838–1.305	36.7
2D6	Molar dextromethorphan / dextrorphan plasma concentration ratio 3 h post-dose	15^c	1.131	0.962–1.328	25.2
3A4	AUC_0–t of midazolam in plasma	16	1.018	0.894–1.159	21.1
3A4	Midazolam plasma concentration 6 h post-dose	16	1.040	0.847–1.277	33.8

AUC_0–t, area under the plasma concentration-time curve between 0 and time of last quantifiable concentration; CI, confidence interval; CV_intra, intrasubject coefficient of variation.
↵^a The main phenotyping metrics are printed in bold.
↵^b Concentration in one subject in the silexan period was below limit of quantification.
↵^c One subject excluded because identified as genetically poor metabolizer.